Home- About us
- Home
- About us
NuclixBio, Inc. focuses on early-stage research and development of
Intracellularly targeted nucleic acid therapeutics, based on proprietary platform technologies.
Introducing Circular mRNA platform as well as Aptamer-Drug Conjugates,
NuclixBio, Inc. pioneers in next-generation targeted therapeutics
that enable “Drugging the Undruggable,” taking the road not taken.
NuclixBio, Inc., composed of nucleic acid engineering experts, is always wide-open to any type of
R&D collaborations and partnerships for further steps. Please feel free to reach us with questions and ideas.